1st Source (NASDAQ:SRCE) reported quarterly earnings of $1.10 per share. This is unchanged from the same period last year.
Humanigen Says Co’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value In Hospitalized COVID-19 Patients
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that a manuscript